APA (7th ed.) Citation

HD, M., JB, L., SJ, W., MS, L., ME, H., AP, M., . . . MA, D. (2025). Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 23(3), 102330. https://doi.org/10.1016/j.clgc.2025.102330

Chicago Style (17th ed.) Citation

HD, McManus, Long JB, Westvold SJ, Leapman MS, Hurwitz ME, Mitchell AP, Pollack CE, Gross CP, and Dinan MA. "Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma." Clinical Genitourinary Cancer 23, no. 3 (2025): 102330. https://doi.org/10.1016/j.clgc.2025.102330.

MLA (9th ed.) Citation

HD, McManus, et al. "Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma." Clinical Genitourinary Cancer, vol. 23, no. 3, 2025, p. 102330, https://doi.org/10.1016/j.clgc.2025.102330.